Goserelin

In this article, we will discuss Goserelin (Dosage Overview). So, let’s get started.

Indications

Stage B2-C Prostatic Carcinoma

Goserelin is indicated for use in combination with flutamide for the management of locally confined
Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with Goserelin and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.

Prostatic Carcinoma

Goserelin is indicated in the palliative treatment of advanced carcinoma of the prostate.In controlled studies of patients with advanced prostatic cancer comparing Goserelin 3.6 mg to orchiectomy, the long-term endocrine responses and objective responses were similar between the two
treatment arms. Additionally, duration of survival was similar between the two treatment arms in a major comparative trial. In controlled studies of patients with advanced prostatic cancer, Goserelin 10.8 mg implant produced pharmacodynamically similar effect in terms of suppression of serum testosterone to that achieved with
Goserelin 3.6 mg implant. Clinical outcome similar to that produced with the use of the Goserelin 3.6 mg implant administered every 28 days is predicted with the Goserelin 10.8 mg implant administered every 12 weeks. The automatic safety feature of the syringe aids in the prevention of needlestick injury.

Dosage

Goserelin, at a dose of 10.8 mg, should be administered subcutaneously every 12 weeks into the anterior abdominal wall below the navel line using an aseptic technique under the supervision of a physician. While a delay of a few days is permissible, every effort should be made to adhere to the 12-week schedule.

Stage B2-C Prostatic Carcinoma

When Goserelin is given in combination with radiotherapy and flutamide for patients with Stage T2b-T4 (Stage B2-C) prostatic carcinoma, treatment should be started 8 weeks prior to initiating radiotherapy and should continue during radiation therapy. A treatment regimen using one Goserelin 3.6 mg depot, followed in 28 days by one Goserelin 10.8 mg depot, should be administered.

Prostatic Carcinoma

For the management of advanced prostate cancer, Goserelin is intended for long-term administration unless clinically inappropriate.

Renal or Hepatic Impairment

No dosage adjustment is necessary for patients with renal or hepatic impairment.

Women

Goserelin 10.8 mg implant is not indicated in women as the data are insufficient to support reliable suppression of serum estradiol.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.